1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27661989%3A_____%2F20%3A10002770" target="_blank" >RIV/27661989:_____/20:10002770 - isvavai.cz</a>

Result on the web

<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7486438/pdf/main.pdf" target="_blank" >https://pmc.ncbi.nlm.nih.gov/articles/PMC7486438/pdf/main.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijcha.2020.100605" target="_blank" >10.1016/j.ijcha.2020.100605</a>

Result language

angličtina

Original language name

1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry

Original language description

Background: The COMBO stent is a biodegradable-polymer sirolimus-eluting stent with endothelial progenitor cell capture technology for faster endothelialization.Objective: We analyzed COMBO stent outcomes in relation to bleeding risk using the PARIS bleeding score.Methods: MASCOT was an international registry of all-comers undergoing attempted COMBO stent implantation. We stratified patients as low bleeding-risk (LBR) for PARIS score &lt;= 3 and intermediate-to-high (IHBR) for score &gt; 3 based on baseline age, body mass index, anemia, current smoking, chronic kidney disease and need for triple therapy. Primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, myocardial infarction (MI) not clearly attributed to a non-target vessel or clinically-driven target lesion revascularization (TLR). Bleeding was adjudicated using the Bleeding Academic Research Consortium (BARC) definition. Dual antiplatelet therapy (DAPT) cessation was independently adjudicated.Results: The study included 56% (n = 1270) LBR and 44% (n = 1009) IHBR patients. Incidence of 1-year TLF was higher in IHBR patients (4.1% vs. 2.6%, p = 0.047) driven by cardiac death (1.7% vs. 0.7%, p = 0.029) with similar rates of MI (1.8% vs. 1.1%, p = 0.17), TLR (1.5% vs. 1.6%, p = 0.89) and definite/ probable stent thrombosis (1.2% vs. 0.6%, p = 0.16). Incidence of 1-year major BARC 3 or 5 bleeding was significantly higher in IHBR patients (2.3% vs. 0.9%, p = 0.0094), as was the incidence of DAPT cessation (29.3% vs. 22.8%, p &lt; 0.01), driven by physician-guided discontinuation.Conclusions: Patients with intermediate-to-high PARIS bleeding risk in the MASCOT registry experienced greater incidence of 1-year TLF, major bleeding and DAPT cessation than LBR patients, without significant differences in stent thrombosis. (C) 2020 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

IJC Heart &amp; Vasculature

ISSN

—

e-ISSN

2352-9067

Volume of the periodical

31

Issue of the periodical within the volume

December

Country of publishing house

IE - IRELAND

Number of pages

8

Pages from-to

1-8

UT code for WoS article

000600577100001

EID of the result in the Scopus database

2-s2.0-85090419361